← Back to Search

Non-invasive Brain Stimulation

tDCS for Speech Impairment After Stroke

N/A
Recruiting
Led By Adam Buchwald, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of apraxia of speech
A minimum of six months post-stroke
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 months
Awards & highlights

Study Summary

This trialaims to see if adding low-intensity current to treatment for speech impairment can improve the effect. tDCS has been shown to help motor learning in other areas and this trial will explore its potential for speech.

Who is the study for?
This trial is for right-handed, English-speaking individuals who have had a stroke at least six months ago and now have apraxia of speech. They must not have any voice disorders, other speech impairments from before the stroke, or risk factors that make tDCS unsafe like skin damage where the device goes, implants affected by electricity or magnets, metal inside their body, or a family history of epilepsy.Check my eligibility
What is being tested?
The study tests if adding brain stimulation with a Soterix low-intensity stimulator to regular speech therapy helps recovery in people with speech issues after a stroke. Some participants will get real stimulation (tDCS), while others receive sham treatment as a comparison; this is decided randomly.See study design
What are the potential side effects?
tDCS is generally safe and well-tolerated. Possible side effects include mild tingling on the scalp, slight itching under the electrode site during stimulation, brief headache or fatigue post-treatment. Serious risks are rare but can involve seizures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with apraxia of speech.
Select...
It has been at least 6 months since my stroke.
Select...
I had a stroke in the left side of my brain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in accuracy in recordings from tasks from baseline to post treatment

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active StimulationExperimental Treatment2 Interventions
crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
Group II: Sham StimulationPlacebo Group2 Interventions
crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sham
2013
Completed Phase 3
~2060

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,368 Previous Clinical Trials
839,702 Total Patients Enrolled
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
328 Previous Clinical Trials
178,272 Total Patients Enrolled
4 Trials studying Apraxia of Speech
202 Patients Enrolled for Apraxia of Speech
Adam Buchwald, MDPrincipal InvestigatorNYU Langone Health

Media Library

Soterix 1x1 line tDCS low-intensity stimulator (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT03452202 — N/A
Apraxia of Speech Research Study Groups: Active Stimulation, Sham Stimulation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is able to join this experiment?

"To qualify for this medical trial, candidates must have apraxia of speech and be between the ages of 18 to 99 years old. In total, 24 individuals will receive acceptance into this study."

Answered by AI

Does the age requirement for this research cap at 70 or below?

"This study is open to candidates aged 18-99. A separate set of trials are available for applicants below 18 years old, and a few additional clinical experiments exist for persons over 65."

Answered by AI

How many individuals can participate in the experiment?

"Indeed, the clinical trial is actively recruiting as per information available on clinicaltrials.gov. It was initially posted and launched on November 1st 2019 and has been updated most recently in October 4th 2022. The study requires 24 participants to be recruited from a single medical site."

Answered by AI

Are researchers still enrolling participants in this clinical trial?

"Affirmative. The information on clinicaltrials.gov states that this medical trial, which was initially listed on November 1st 2019 is currently recruiting participants. Approximately 24 people need to be signed up from a single site."

Answered by AI

Who else is applying?

What state do they live in?
New York
What site did they apply to?
New York University School of Medicine
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I’m motivated to return to normal daily activities and be fully active at work . Marketing and sales.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Using tDCS in Speech-based Stroke Rehabilitation
2019. "Using tDCS in Speech-based Stroke Rehabilitation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03452202.
~5 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top